Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of SAL0114 tablets in major depressive disorder
CTR20250861Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0114, bupropion in major depressive disorder (MDD), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
SAL0114bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250861.